This presentation highlights Pfizer's advancements with the iSKID Integrated Manufacturing System. The iSKID system aims to maximize productivity through thoughtful integration of processes, featuring a highly productive short duration perfusion process with a 2-3 week cadence and a simple downstream design. Data from recent GMP manufacturing campaigns will highlight the iSKID’s potential to increase process productivities as well as the reshape the Pfizer’s manufacturing network.
Learning Objectives:
Understand current and future drug substance manufacturing strategies to meet the portfolio needs of large pharma.
Considerations for evolving continuous bio-manufacturing options for biologics
Understand keys features of Pfizer’s iSkid, its integrated continuous manufacturing system
